Described herein are compositions capable of targeting CaMKKβ and/or AMPK alpha and formulations thereof. Also described herein are methods of using the compositions and formulations thereof. In some embodiments, the compositions capable of targeting CaMKKβ and/or AMPK alpha and formulations thereof can prevent or treat outer hair cell loss, such as that which can occur as a result of auditory or chemical insult. In some embodiments, the compositions capable of targeting CaMKKβ and/or AMPK alpha and formulations thereof can treat or prevent acquired hearing loss.

The instant disclosure provides methods and compositions for the diagnosis, treatment and prevention of Marfan syndrome and related diseases, disorders and conditions. The disclosure further provides pharmaceutical compositions and kits for the diagnosis, treatment and prevention of Marfan syndrome and related diseases, disorders and conditions.

Described is a method for promoting regeneration of hematopoietic stem and progenitor cells in a subject in need thereof. The method comprises administering to the subject a composition comprising a CaMKK2 inhibitor. The CaMKK2 inhibitor may be a small molecule inhibitor, such as STO-609.

Disclosed herein are methods of treating an ischemic or inflammatory condition in an organ or tissue of a patient comprising inducing an increase of the level of CAMKK1 in said organ or tissue.

The present invention relates to anticancer extracellular vesicles, a preparation method therefor, and an anticancer composition comprising same. Immune-tolerized extracellular vesicles containing LDHB and PGC-1α of the present invention provide cancer treatment, suppression of cancer metastasis, and cancer prevention technologies by normalizing cancer cell-specific aerobic glycolysis energy metabolic pathway in which lactate and hydrogen ions, which form a tumor microenvironment favorable for immune evasion, proliferation, metastasis and invasion of cancer cells, are produced, thereby enabling tumors to be effectively removed by means of the immune system of a patient.

Described is a method for promoting regeneration of hematopoietic stem and progenitor cells in a subject in need thereof. The method comprises administering to the subject a composition comprising a Ca2+/calmodulin (CaM)-dependent protein kinase kinase 2 (CaMKK2) inhibitor. The CaMKK2 inhibitor may be a small molecule inhibitor, such as 7H-benzimidazo(2,1-a)benz(de)isoquinoline-7-one-3-carboxylic acid (STO-609).

An application of CaMK4 as a target in preparation of medicines for preventing and treating psoriasis and an application of a CaMK4 inhibitor in preparation of medicines for preventing and treating psoriasis are provided. The expressions of CaMK4 in skin lesions of patients with psoriasis and IMQ induced skin lesions of mice with psoriasis are detected, and the results show that CaMK4 is positively correlated with psoriasis development. CaMK4 is expressed not only in immune cells, but also in keratinocytes. Moreover, IL-10 and the CaMK4 inhibitor can reduce psoriasiform inflammation induced by IMQ in mice. It shows that CaMK4 can be used as a new target in the preparation of medicines for prevention and treatment of psoriasis.

Compositions include biosensors and enzyme substrates for use in the biosensors. Methods of identifying modulators of enzymatic activity include the biosensors.

The present invention relates to anticancer extracellular vesicles, a preparation method therefor, and an anticancer composition comprising same. Immune-tolerized extracellular vesicles containing LDHB and PGC-1α of the present invention provide cancer treatment, suppression of cancer metastasis, and cancer prevention technologies by normalizing cancer cell-specific aerobic glycolysis energy metabolic pathway in which lactate and hydrogen ions, which form a tumor microenvironment favorable for immune evasion, proliferation, metastasis and invasion of cancer cells, are produced, thereby enabling tumors to be effectively removed by means of the immune system of a patient.

Disclosed herein are methods of treating an ischemic or inflammatory condition in an organ or tissue of a patient comprising inducing an increase of the level of CAMKK1 in said organ or tissue.